NFKB1 and inflammatory bowel disease: A recent report showed a new soluble protein from LGG, HM0539, suppress inflammation by inhibiting the TLR4/MyD88/NF-κB signaling, which is considered as a potential therapeutic option for inflammatory bowel disease (IBD) (49).